GURUFOCUS.COM » STOCK LIST » Healthcare » Drug Manufacturers » Jacobson Pharma Corp Ltd (HKSE:02633) » Definitions » 10-Year RORE %

Jacobson Pharma (HKSE:02633) 10-Year RORE % : 0.00% (As of Mar. 2024)


View and export this data going back to 2016. Start your Free Trial

What is Jacobson Pharma 10-Year RORE %?

Return on Retained Earnings (RORE) is an indicator of a company's growth potential, it shows how much a company earns by reinvesting its retained earnings, i.e. profits after dividend payments. Jacobson Pharma's 10-Year RORE % for the quarter that ended in Mar. 2024 was 0.00%.

The industry rank for Jacobson Pharma's 10-Year RORE % or its related term are showing as below:

HKSE:02633's 10-Year RORE % is not ranked *
in the Drug Manufacturers industry.
Industry Median: 6.095
* Ranked among companies with meaningful 10-Year RORE % only.

Jacobson Pharma 10-Year RORE % Historical Data

The historical data trend for Jacobson Pharma's 10-Year RORE % can be seen below:

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

* Premium members only.

Jacobson Pharma 10-Year RORE % Chart

Jacobson Pharma Annual Data
Trend Mar15 Mar16 Mar17 Mar18 Mar19 Mar20 Mar21 Mar22 Mar23 Mar24
10-Year RORE %
Get a 7-Day Free Trial Premium Member Only Premium Member Only - - - - -

Jacobson Pharma Semi-Annual Data
Mar15 Sep15 Mar16 Sep16 Mar17 Sep17 Mar18 Sep18 Mar19 Sep19 Mar20 Sep20 Mar21 Sep21 Mar22 Sep22 Mar23 Sep23 Mar24 Sep24
10-Year RORE % Get a 7-Day Free Trial Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only Premium Member Only - - - - -

Competitive Comparison of Jacobson Pharma's 10-Year RORE %

For the Drug Manufacturers - Specialty & Generic subindustry, Jacobson Pharma's 10-Year RORE %, along with its competitors' market caps and 10-Year RORE % data, can be viewed below:

* Competitive companies are chosen from companies within the same industry, with headquarter located in same country, with closest market capitalization; x-axis shows the market cap, and y-axis shows the term value; the bigger the dot, the larger the market cap. Note that "N/A" values will not show up in the chart.


Jacobson Pharma's 10-Year RORE % Distribution in the Drug Manufacturers Industry

For the Drug Manufacturers industry and Healthcare sector, Jacobson Pharma's 10-Year RORE % distribution charts can be found below:

* The bar in red indicates where Jacobson Pharma's 10-Year RORE % falls into.



Jacobson Pharma 10-Year RORE % Calculation

Jacobson Pharma's 10-Year RORE % for the quarter that ended in Mar. 2024 is calculated as:

10-Year RORE %=( Most Recent EPS (Diluted)- First Period EPS (Diluted) )/( Cumulative EPS (Diluted) for 10-year -Cumulative Dividends per Share for 10-year )
=( - )/( 1.1-0.319 )
=/0.781
=0.00 %

* For Operating Data section: All numbers are indicated by the unit behind each term and all currency related amount are in USD.
* For other sections: All numbers are in millions except for per share data, ratio, and percentage. All currency related amount are indicated in the company's associated stock exchange currency.

In the calculation of 10-Year RORE %, the most recent and first period EPS (Diluted) is the trailing twelve months (TTM) data ended in Mar. 2024 and 10-year before.


Jacobson Pharma  (HKSE:02633) 10-Year RORE % Explanation

Return on Retained Earnings (RORE) is important to investors because it reveals a company's efficiency and growth potential. A higher RORE indicates a higher return. A high RORE indicates that the company should reinvest profits into the business. A lower RORE suggests that the company should distribute profits to shareholders by paying out dividends, since those dollars aren't generating much additional growth for the company.

There are a several different ways to arrive at the Return on Retained Earnings. The simplest way to calculate it is by using published information on Earnings per Share (EPS) and Dividend per Share (DPS) over a selected period. Here, 10-year period is chosen.

Be Aware

Please keep in mind that the RORE is relative to the nature of the business and its competitors. If another company in the same sector is producing a lower return on retained earnings, it doesn’t necessarily mean it’s a bad investment. It may just suggest the company is older and no longer in a high growth stage. At such a stage in the business cycle, it would be expected to see a lower RORE and higher dividend payout.


Jacobson Pharma 10-Year RORE % Related Terms

Thank you for viewing the detailed overview of Jacobson Pharma's 10-Year RORE % provided by GuruFocus.com. Please click on the following links to see related term pages.


Jacobson Pharma Business Description

Traded in Other Exchanges
N/A
Address
388 Kwun Tong Road, Unit 2313-18, 23rd Floor, Tower 1, Millennium City 1, Kwun Tong, Kowloon, Hong Kong, HKG
Jacobson Pharma Corp Ltd is an investment holding company. It is principally engaged in the development, production, marketing, and sale of generic drugs. The company's operating segment includes Generic drugs; Branded healthcare, Wholesale, and retail The generic drugs segment develops, manufactures, and distributes a host of off-patent medicines for various therapeutic use. It generates maximum revenue from the Generic drugs segment. Geographically, it derives a majority of its revenue from Hong Kong and also has a presence in Mainland China, Macau, Singapore, and Other Countries.
Executives
Sum Kwong Yip, Derek 2305 Beneficiary of a trust
Kingshill Development Group Inc
Kingshill Development Limited
Ubs Trustees (b.v.i.) Limited
Queenshill Development Limited
Longjin Investments Limited
Lau Wing Hung
Yun Nan Bai Yao Ji Tuan Gu Fen You Xian Gong Si

Jacobson Pharma Headlines

No Headlines